Vijan Hospital & Research Centre

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Obesity4 trials
• Heart failure3 trials
• Peripheral artery disease2 trials
• Chronic kidney disease1 trial
• Type 2 diabetes1 trial

Phase

• Phase 38 trials

Status

• Completed3 trials
• Not yet recruiting2 trials
• Recruiting2 trials
• Active, not recruiting1 trial

Lead sponsor

• Novo Nordisk A/S6 trials
• Eli Lilly and Company2 trials

Running trials

• Not yet recruiting

  AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight

  NCT07668401· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

  NCT07223593· Phase 3· Eli Lilly and Company· Source

  Contact: Vikrant Vijan (principal investigator)

• Active, not recruiting

  A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

  NCT06200207· Phase 3· Novo Nordisk A/S· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Heart failure1 recruiting
• Peripheral artery disease1 recruiting

Closed trials

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

  NCT04847557· Phase 3· Eli Lilly and Company· Source

• Completed

  A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

  NCT04560998· Phase 3· Novo Nordisk A/S· Source